The dividend payment is scheduled for September 11, 2026. To qualify for the distribution, investors must be listed as stockholders of record by the close of business on August 21, 2026.

As a component of the Dow Jones Industrial Average and the Nasdaq-100, Amgen continues to maintain a significant footprint in the pharmaceutical sector. The company currently focuses on a diverse therapeutic portfolio, ranging from treatments for heart disease and cancer to inflammatory conditions and obesity-related health challenges.